Search

Your search keyword '"Florence Canouï-Poitrine"' showing total 2 results
Start Over Author "Florence Canouï-Poitrine" Journal ssrn electronic journal
2 results on '"Florence Canouï-Poitrine"'

1. Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study

Author

Damien Contou, Gwenhaël Colin, Brendan Travert, Sébastien Jochmans, Marie Conrad, Jean-Baptiste Lascarrou, Benoit Painvin, Alexis Ferré, David Schnell, Béatrice La Combe, Rémi Coudroy, Stephan Ehrmann, Jérôme Rambaud, Arnaud Wiedemann, Pierre Asfar, Pierre Kalfon, Emmanuel Guérot, Sébastien Préau, Laurent Argaud, Florence Daviet, Jean Dellamonica, Audrey Dupont, Muriel Fartoukh, Toufik Kamel, Gaetan Beduneau, Florence Canouï-Poitrine, Emmanuelle Boutin, Gérard Lina, Armand Mekontso Dessap, Anne Tristan, Nicolas de Prost, French m-TSS Study Group, Centre Hospitalier Victor Dupouy, CH Départemental Vendée, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier de Melun (CHM), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Pontchaillou [Rennes], Laboratoire Lasers, Plasmas et Procédés photoniques (LP3), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier d'Angoulême (CH Angoulême), Université de Bretagne Sud - Lorient (UBS Lorient), Université de Bretagne Sud (UBS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinical Research in Intensive Care and Sepsis - TRIal Group for Global Evaluation and Research in SEPsis [CHU Limoges] (Réseau CRICS-TRIGGERSEP ), Hôpital Dupuytren [CHU Limoges], Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Réanimation polyvalente [Chartres], Hôpital Louis Pasteur [Chartres], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Assistance Publique - Hôpitaux de Marseille (APHM), Unité de Recherche Clinique de la Côte d’Azur (URRIS UR2CA), Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Université Côte d'Azur (UCA), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Réanimation (ORLEANS - Réa), Centre Hospitalier Régional d'Orléans (CHRO), Service de réanimation médicale [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Normandie Université (NU)-Normandie Université (NU), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Groupe de recherche clinique CARMAS (Cardiovascular and Respiratory Manifestations of Acute lung injury and Sepsis) (CARMAS), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-CHU Henri Mondor [Créteil], Unité de Recherche Clinique de la Côte d’Azur [Nice] (URRIS UR2CA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Henri Mondor, CarMeN, laboratoire, Centre Hospitalier de Melun, Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
0301 basic medicine, Microbiology (medical), Adult, Staphylococcus aureus, medicine.medical_specialty, Adolescent, genetic structures, [SDV]Life Sciences [q-bio], medicine.medical_treatment, 030106 microbiology, Disease, law.invention, Sepsis, Menstruation, sepsis, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, Intensive care, medicine, Humans, 030212 general & internal medicine, Child, menstrual toxic shock syndrome, Retrospective Studies, Superantigens, Critically ill, business.industry, Medical record, Tracheal intubation, Toxic shock syndrome, Retrospective cohort study, Staphylococcal Infections, tampon, bacterial infections and mycoses, Institutional review board, medicine.disease, Shock, Septic, Intensive care unit, 3. Good health, Anti-Bacterial Agents, [SDV] Life Sciences [q-bio], Infectious Diseases, Icu, Female, Observational study, menstruation, business
Abstract

Background Studies describing the clinical features and short-term prognosis of patients admitted to the intensive care unit (ICU) for menstrual toxic shock syndrome (m-TSS) are lacking. Methods This was a multicenter retrospective cohort study of patients with a clinical diagnosis of m-TSS admitted between 1 January 2005 and 31 December 2020 in 43 French pediatric (n = 7) or adult (n = 36) ICUs. The aim of the study was to describe the clinical features and short-term prognosis, as well as to assess the 2011 Centers for Disease and Control (CDC) diagnostic criteria, in critically ill patients with m-TSS. Results In total, 102 patients with m-TSS (median age, 18 years; interquartile range, 16–24 years) were admitted to 1 of the participating ICUs. All blood cultures (n = 102) were sterile. Methicillin-sensitive Staphylococcus aureus grew from 92 of 96 vaginal samples. Screening for superantigenic toxin gene sequences was performed for 76 of the 92 vaginal samples positive for S. aureus (83%), and toxic shock syndrome toxin 1 was isolated from 66 strains (87%). At ICU admission, no patient met the 2011 CDC criteria for confirmed m-TSS, and only 53 (52%) fulfilled the criteria for probable m-TSS. Eighty-one patients (79%) were treated with antitoxin antibiotic therapy, and 8 (8%) received intravenous immunoglobulins. Eighty-six (84%) patients required vasopressors, and 21 (21%) tracheal intubation. No patient required limb amputation or died in the ICU. Conclusions In this large multicenter series of patients included in ICUs for m-TSS, none died or required limb amputation. The CDC criteria should not be used for the clinical diagnosis of m-TSS at ICU admission.

Published
2021

2. Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients Among 29307 Cancer Patients in AP-HP Hospitals During the COVID-19 Pandemic. A Multicenter Cohort Study in Electronic Health Records

Author

Marc-Antoine Benderra, Judith Leblanc, Demian Wassermann, Emmanuelle Kempf, Gilles Galula, Mélodie Bernaux, Nicolas Paris, Thomas Moreau, Ali Bellamine, Christel Daniel, Julien Champ, Florence Canouï-Poitrine, Joseph Gligorov, AP-HP / Universities / Inserm COVID Group, and AP-HPCovid CDW Initiative Group

Subjects
medicine.medical_specialty, education.field_of_study, business.industry, Mortality rate, Population, Cancer, Retrospective cohort study, Context (language use), medicine.disease, Institutional review board, Diabetes mellitus, Internal medicine, medicine, business, education, Cohort study
Abstract

Background: It was suggested that Coronavirus disease 2019 (COVID-19) may affect more frequently and with more severe evolution cancer patients. Our objectives were to assess the COVID-19 rate in cancer patients, to characterize their demographic, clinical and biological features and to assess their care trajectories and case-fatality rate. Methods: Based of Electronic Health Records of the Assistance Publique - Hopitaux de Paris, cancer patients were identified according to previous or actual history of cancer, and among them all patients tested for SARS-CoV-2 between March 03, 2020, and May 19, 2020 were included in this retrospective cohort study. We assessed the COVID-19 rate, described the clinical and biological cancer-related and non-cancer characteristics, care trajectories and mortality rate. Main outcome was COVID-19 assessed by positivity of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for SARS-CoV-2. Findings: Among the 29307 cancer patients, 8104 (28%) underwent a SARS-CoV-2 RT-PCR test. A total of 1672 patients (21% among tested cancer patients, 99% CI: 19 - 22) had COVID-19. Among them, median age was 75 years, 57% were men, 21% had gastro-intestinal tumors, 21% hematological malignancies, 22% were metastatic; 52% had a recent cancer diagnosed in 2019 or early 2020. Regarding the comorbidities, 51% had hypertension, 32% coronary heart diseases or heart failure, 27% diabetes, and 24% cardiac arrhythmia. Overall, 86% were hospitalized, and among them 18% in Intensive Care-Unit. Mortality rate for this population was 26% (99% CI: 24-28). During the same period, among the 309474 non-cancer patients, 98134 were tested for COVID-19 (32%), 24% (99% CI: 24-24) had a confirmed COVID-19 diagnosis. Mortality rate was 8·6%. Interpretation: Our results suggest that in hospital-based setting, cancer patients were not more affected by COVID-19 than non-cancer patients and that the high case fatality-rate may be mainly driven by advanced age and comorbidities. Funding Statement: Supported by Assistance Publique -Hopitaux de Paris Foundation. Declaration of Interests: MAB, JL, DW, EK, GG, MB, NP, TM, AB, CD, JC, FCP and JG do not declare any relevant conflicts of interest in the context of this work. JG reports grants from Eisai, Genomic-Health, Pfizer, Roche-Genentech, personal fees from Daiichi, Eisai, Genomic-Health, Macrogenics, MSD, Novartis, Onxeo, Pfizer, Roche-Genentech and non-financial support from Eisai, Genomic-Health, Novartis, Pfizer, Roche-Genentech, outside the submitted work. Ethics Approval Statement: On April 16, 2020, the Scientific and Ethics Committee of the AP-HP Health Data Warehouse gave a positive opinion to our research project concerning the analysis of data from cancer patients diagnosed COVID-19 at AP-HP. This study was approved by Institutional Review Board (IRB 00011591). The database was authorized by the National Freedom and Informatic Commission (CNIL Number 1980120).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results